A5337: Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy

Study Location:

Washington

Topic:

HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02440789?term=a5337&rank=1

IRB#:

Pro00013249

Coordinator:

Anna Wimpelberg

Enrollment:

Open

Trial Period:

Ongoing

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because the number of CD4 cells goes down). Despite successful treatment with anti-HIV therapy, latent reservoirs (infected cells that are not actively producing HIV) remain in the blood and contribute to a process called immune system activation and inflammation in the body. This may contribute to HIV persisting in cells in the body even while taking medications to treat HIV.

  • HIV-infected men and woman, at least 18 years of age
  • Taking anti-HIV medications that have controlled the HIV viral load (“undetectable” levels) for 2 or more years.
    • Protease inhibitors and cobicistat are not allowed on this study.
  • CD4 cell count greater than or equal to 400 cells/mm3
  • No active hepatitis B or C infection, tuberculosis, or shingles
  • No vaccinations in the past 14 days.

Anna Wimpelberg 
202-797-3589
awimpelberg@whitman-walker.org

Categories

Location
Topic

Clinical Trials

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More

P2001 (DAIDS ID 12026): Evaluating the Pharmacokinetics,...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5290: Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More